Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Person › Details

Arthur Lahr (Kiadis Pharma N.V. (Euronext: KDS))

Lahr, Arthur (Kiadis 201704– CEO before Crucell 200701 Chief Strategy Officer + EP Sales + BusDev)

 

Organisations Organisation Kiadis Pharma N.V. (Euronext: KDS)
  Group Kiadis (Group)
  Former/major organisation Crucell N.V. (Euronext: CRXL, Nasdaq: CRXL)
  Group Johnson & Johnson (JnJ) (Group)
Product Product ATIR™ (Kiadis)
Document Source Kiadis Pharma N.V.. (6/13/17). "Press Release: Kiadis Pharma Raises €5 Million in Private Placement with Institutional Investors [Not for US, AU, CA, JP, ZA or any other jurisdiction where unlawful]". Amsterdam.
     

   
Record changed: 2018-03-31

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px


More documents for Arthur Lahr


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top